---
layout: minimal-medicine
title: Anti-Inhibitor Coagulant Complex
---

# Anti-Inhibitor Coagulant Complex
### Generic Name
Anti-Inhibitor Coagulant Complex (aPCC)

### Usage
Anti-inhibitor coagulant complex (aPCC) is a medication used to treat and prevent bleeding episodes in individuals with hemophilia A and B who have developed inhibitors. Inhibitors are antibodies that neutralize the body's natural clotting factors, making it difficult to stop bleeding.  aPCC is a bypass agent, meaning it works by circumventing the need for the inhibited clotting factors to achieve hemostasis (stopping bleeding).  It's primarily used for controlling and preventing bleeds, managing bleeding during surgery (perioperative management), and as routine prophylaxis to reduce the frequency of bleeding episodes.  It is *not* used to treat bleeding caused by clotting factor deficiencies *without* the presence of inhibitors.

### Dosage

**Important Note:** aPCC contains activated and non-activated clotting factors. Dosage is determined by the severity and location of the bleeding episode and is measured in units of factor VIII inhibitor bypassing activity.  The maximum daily dose should not be exceeded unless absolutely necessary due to severe bleeding.  Always follow the instructions of your healthcare provider. The information below is for general guidance only and should not replace a doctor's prescription.

**Adults:**  Dosage varies widely depending on the type and severity of bleeding.  Typical intravenous (IV) doses range from 50-100 units/kg per dose.  The frequency of administration also varies, from every 6 hours to every 12 hours,  and the treatment duration depends on the patient's response.  Maximum doses are typically 100 units/kg per dose and 200 units/kg per day.  Specific examples:

* **Joint Hemorrhage:** 50-100 units/kg every 12 hours until pain and disability improve.
* **Mucous Membrane Bleeding:** 50-100 units/kg every 6 hours for at least 24 hours, or until bleeding stops.
* **Soft Tissue Hemorrhage (e.g., retroperitoneal bleed):** 100 units/kg every 12 hours until the bleed resolves.
* **Severe Hemorrhage (e.g., intracranial bleed):** 100 units/kg every 6-12 hours until the bleed resolves.
* **Perioperative Management (before/after surgery):** 50-100 units/kg as a single dose before surgery, and then repeated every 6-12 hours post-surgery as needed.
* **Routine Prophylaxis:** 85 units/kg every other day.


**Children:** Dosage is similar to adults, adjusted according to weight and bleeding severity.  The safety and efficacy in neonates have not been established.  Always consult a pediatrician or hematologist for pediatric dosing.


### Side Effects

Common side effects can include:

* Headache
* Dizziness
* Malaise
* Nausea
* Vomiting
* Chills
* Fever
* Pain at the injection site
* Rash
* Itching


Less common, but serious side effects may include:

* Allergic reactions (including anaphylaxis)
* Thromboembolic events (blood clots in arteries or veins, leading to stroke, heart attack, or pulmonary embolism)
* Low blood pressure
* Disseminated intravascular coagulation (DIC, a serious clotting disorder)


**If you experience any side effects, especially serious ones, seek immediate medical attention.**

### How it Works

aPCC contains several clotting factors (II, VII, IX, and X), some in activated and some in non-activated forms.  In individuals with hemophilia and inhibitors, the usual clotting cascade is disrupted. aPCC provides these factors, enabling the bypassing of the inhibited steps and restarting the process of clot formation to stop bleeding.  The activated Factor VII plays a crucial role in this process.

### Precautions

* **Contraindications:**  aPCC is contraindicated in individuals with known severe hypersensitivity to aPCC or any of its components, disseminated intravascular coagulation (DIC), or acute thrombosis/embolism (blood clots).
* **Thromboembolic Risk:** aPCC carries a risk of thromboembolic events, particularly with high doses or in patients with pre-existing risk factors.  Careful monitoring is necessary.
* **Allergic Reactions:**  Allergic reactions, including severe anaphylaxis, are possible. Patients should be closely monitored during and after administration.
* **Infusion Reactions:**  Infusion-related reactions, such as fever, chills, and hypotension, can occur.
* **Infectious Disease Transmission:** There's a theoretical risk of transmitting infectious agents, although the manufacturing process is designed to minimize this.
* **Pregnancy and Breastfeeding:** aPCC is a Category C drug during pregnancy; the potential risks to the fetus are not fully understood.  It is unknown whether it's excreted in breast milk.  Consult your healthcare provider to discuss the benefits and risks.
* **Interactions:**  Using antifibrinolytic agents concurrently with aPCC is generally not recommended.
* **Hepatic/Renal Impairment:** No specific dosage adjustments are recommended for patients with liver or kidney disease, but use with caution is advised.


### FAQs

* **How is aPCC administered?** aPCC is given intravenously (IV).
* **How long does it take to work?** The effect of aPCC varies depending on the individual and severity of bleeding.  It generally works relatively quickly but may require repeated doses.
* **How is aPCC stored?** Storage instructions vary depending on the specific product; check the medication packaging.
* **Are there any long-term effects?** Long-term effects are generally not associated with aPCC, although the potential for the development of antibodies or thromboembolic events exists.  Regular monitoring is important.
* **Who should not use aPCC?** Individuals with hypersensitivity to aPCC, DIC, or acute thromboembolic events should not use this medication.
* **What should I do if I miss a dose?** Contact your healthcare provider immediately to determine the best course of action.

**Disclaimer:** This information is for educational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of any medical condition.  The dosage and use of aPCC must be determined by a physician experienced in treating hemophilia.  The provided information is based on commonly available resources but may not encompass all possible formulations or details.  Always refer to the specific product labeling for complete information.
